Erythropoietin treatment and osteoporotic fracture risk in hemodialysis patients: A nationwide population-based study

Erythropoietin treatment and osteoporotic fracture risk in hemodialysis patients: A nationwide population-based study

Objectives: Concerns about erythropoietin (EPO) therapy for anemia in patients with end-stage renal disease (ESRD) contributing to potential bone loss and increased fracture risks are growing. This study investigated the impact of EPO administration on the risk of common osteoporotic fractures in ES...

Full description

Bibliographic Details
Main Authors: Ching-Yu Lee, Fung-Chang Sung, Peir-Haur Hung, Chih-Hsin Muo, Meng-Huang Wu, Tsung-Jen Huang, Chih-Ching Yeh
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Osteoporosis and Sarcopenia
Subjects:
Erythropoietin
End-stage renal disease
Hemodialysis
Osteoporotic fracture risk
Online Access:http://www.sciencedirect.com/science/article/pii/S2405525524001213

Internet

http://www.sciencedirect.com/science/article/pii/S2405525524001213

Similar Items